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ABSTRACT: Type of study: Descriptive cross-sectional 
observational study. Objective: To evaluate the knowledge of 
university students concerning the risks and benefits associated to 
combined oral contraceptives (COC). Methods: The study group 
consisted of a convenience sample of female medical students. 
Data was collected from October to November 2017 through a 
structured, self-applying questionnaire consisting of 30 questions 
divided into sociodemographic data, contraceptive antecedents 
and knowledge of risks and benefits associated with the use of 
COC. Results: 86 university students participated in this study. 
Most of them were aged between 18 and 25 years (76.74%), were 
COC users (86.05%) and started using it by medical indication 
(94.59%). Few of them knew the beneficial effects of COCs in 
the reduction of endometrial (31.40%), ovarian (18.60%) and 
colorectal (8.14%) cancers. On the other hand, knowledge of 
the risks of deep vein thrombosis (97.67%) and stroke (88.37%) 
was satisfactory. Additionally, more than half of the university 
students associated the use of COC with weight gain (56.98%). 
Conclusion: The imbalance between knowledge about COC 
risks and benefits cannot be underestimated, and it is relevant 
that health professionals identify COC benefits and side effects 
misconceptions in order to provide an effective contraceptive 
counselling. 
Keywords: Knowledge; Contraceptives, oral, combined; Risk 
aassessment; Students, medical; Women’s health.
RESUMO: Modelo do estudo: Estudo observacional transversal 
descritivo. Objetivo: Avaliar o conhecimento de universitárias 
sobre riscos e benefícios associados aos contraceptivos orais 
combinados (COC). Método: A população do estudo foi composta 
por uma amostra de conveniência de estudantes de medicina do 
sexo feminino. Os dados foram coletados no período de outubro 
a novembro de 2017 por meio de um questionário estruturado, 
autoaplicável e composto por 34 questões divididas em dados 
sociodemográficos, antecedentes contraceptivos e conhecimentos 
sobre riscos e benefícios associados ao uso dos COC. Resultados: 
Participaram desta pesquisa 86 estudantes. A maioria das 
participantes estava na faixa etária entre 18 e 25 anos (76,74%), 
era usuária dos COC (86,05%) e iniciou seu uso por indicação 
médica (94,59%). Poucas delas conheciam os efeitos benéficos 
dos COC na redução dos cânceres de endométrio (31,40%), ovário 
(18,60%) e colorretal (8,14%). Por outro lado, os conhecimentos 
dos riscos de trombose venosa profunda (97,67%) e acidente 
vascular encefálico (88,37%) foram satisfatórios. Adicionalmente, 
mais da metade das universitárias associou o uso dos COC a 
ganho de peso (56,98%). Conclusão: O desequilíbrio entre os 
conhecimentos sobre benefícios e riscos dos COC não pode 
ser subestimado, sendo relevante que os profissionais de saúde 
identifiquem equívocos relacionados aos benefícios e efeitos 
colaterais dos COC, a fim de proporcionarem um aconselhamento 
contraceptivo efetivo.
Descritores: Conhecimento; Anticoncepcionais orais combinados; 
Medição de risco; Estudantes de medicina; Saúde da mulher.
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INTRODUCTION
One of the most important achievements in public health in the twentieth century was the 
development of combined oral contraceptive (COC), a mark 
in the female sexual and reproductive rights, offering an 
efficient fertility control unattended by male motivation, 
allowing women autonomy in tracing their life trajectory, 
gaining ground in the labor market, occupying political 
positions, thus changing the usual behavior and social role. 
Since the beginning of its commercialization in 1960, COCs 
represent the most popular form of reversible contraception 
worldwide1,2, with the prevalence of use among women of 
reproductive age estimated at 9% worldwide and 24.1% 
in Brazil in 20153.
COCs consist of an association of an estrogen and a 
progestogen, with ovulation inhibition as main mechanism 
of action by suppression of pituitary gonadotropins 
secretion4. The progestogenic component produces the 
main contraceptive effects, being the inhibition of the 
preovulatory peak of luteinizing hormone (LH) its most 
prominent effect. It makes the cervical mucus thick, 
inhibiting the sperm progression to the ampulla region of 
the fallopian tube, where fertilization normally occurs; 
decreases tubal peristaltic movements, interfering in egg 
capture and embryo migration to the uterine cavity; inhibits 
the endometrium proliferation, making it atrophic and, 
consequently, less receptive to embryonic implantation. The 
estrogenic component suppresses the follicle stimulating 
hormone (FSH), preventing follicular growth and the 
emergence of a dominant follicle. Besides, stabilizes 
endometrium, minimizing bleeding during COCs use 
and enhances the action of progestogens by intracellular 
progesterone receptors increase, thus allowing the use of 
lower doses of this hormone for contraceptive protection1.
When consistently and correctly used, COCs 
prevent unplanned pregnancies, an important strategy to 
protect the lives of women of reproductive age, especially 
those ones who live in high social vulnerability areas and 
with little access to health services1. A large population-
based study, with a long follow-up period, suggests that the 
COC is associated with mortality reduction, indicating a 
general benefit to women’s health5.
COCs also provides significant non-contraceptive 
benefits. Endometrial atrophy induced by progestogen 
component reduces menstrual flow and colic, qualifying 
its use for the treatment of heavy menstrual bleeding, 
abnormal uterine bleeding and dysmenorrhea (primary or 
due to endometriosis)6. By increasing the production of sex 
hormone-binding globulin (SHBG), COCs decrease free 
androgen levels and thus, could be useful in preventing or 
reducing the effects associated with excessive exposure to 
androgens such as acne and hirsutism1. COCs could also 
reduce the risks of pelvic inflammatory disease, ectopic 
pregnancy and occurrence of ovarian, endometrial and 
colorectal cancers2,4.
On the other hand, the use of COC is associated 
with an increased risk of venous thromboembolism (VTE), 
including deep vein thrombosis (DVT) and pulmonary 
thromboembolism (PTE). However, the incidence of VTE 
remains low among users (8-10 events per 10,000 women/
year of exposure) when compared to non-users (5-10 
events per 10,000 women/year of exposure)7. Initially, 
it was believed that the increased risk of thrombogenic 
events was solely due to estrogens action on hemostatic 
factors7. Subsequently, it was found that depending on the 
present progestogen type in COCs, the thrombosis risk 
could be higher or lower, suggesting an influence of this 
component on clots formation. In fact, pills containing 
cyproterone acetate, desogestrel, drospirenone or gestodene 
are associated with a significantly increased risk of VTE 
compared to the use of those containing levonorgestrel. 
However, the mechanism by which this happens is still 
not well understood7.
Since the first pill development and approval, 
hormone dose in formulations is being under significant 
reductions aiming to improve the safety and tolerability 
of the method1. As a result, side effects from estrogens 
(increased blood pressure, headache and mastalgia) and 
progestogens (escape bleeding) have been reduced; and 
when present, they are usually self-limiting and improve 
during method use4,6.
Despite the consolidated evidence on the benefits 
and side effects of COC, a recent research carried out 
among Romanian university students found that only 32.2% 
considered this method effective and safe and few knew its 
potential for the treatment of dysmenorrhea and acne (28% 
and 12.6%, respectively). Negative perceptions, such as the 
association between the use of COC with weight gain and 
reduced future fertility, were also observed8. Furthermore, 
a study carried out in the North-Eastern region of Brazil 
with 294 women of childbearing age showed that 75% of 
them had no knowledge about possible side effects9.
This scenario of misconceptions is related to 
COC adherence decrease, interruption of its use and, 
consequently, an increase on the contraceptive failure rate10. 
This is most concerning among younger women whose 
have less knowledge and less use of contraceptive methods, 
therefore requiring a qualified contraceptive counseling11.
In this sense, given the importance of this theme, 
the present study aimed to estimate the young university 
students’ knowledge about the risks and benefits associated 
with COC. The results could guide the development of 
educational strategies to assist women in more effective and 
safe reproductive planning, since reaching contraceptive 
needs is of major importance for improving public health 
and the physical, mental and social well-being of women 
and their families.
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METHODS
This is a descriptive observational cross-sectional 
study carried out in a convenience sample composed of 
86 female students, aged over 18 years, enrolled at the 
Medicine Course at the Federal University of Sao Carlos 
(UFSCar).
In compliance with Resolution 466/2012 of the 
National Health Council, this study was approved by the 
Research Ethics Committee in Human Beings at the Federal 
University of Sao Carlos (opinion number 2.107.608).
The recruitment of participants took place from 
October to November 2017, through invitation after the 
end of the students’ activities on more than one occasion, 
reducing the possibility of loss.
Data collection was performed individually and in 
a reserved place after voluntary signature of the Free and 
Informed Consent Form. A structured and self-administered 
questionnaire (Annex 1) was used by the researchers 
based on a similar research2. It consisted of 30 questions 
distributed into three sections: 1) sociodemographic data 
(age, marital status, religion, color and health care system 
type); 2) contraceptive history (The main reason for COC 
use; Who recommended its use; Influence of COC risks/
side effects in the decision to abandon or to never use it); 3) 
The knowledge about risks, benefits, side effects and myths 
related to COC use. In section 3, the response options were: 
Increase, Decrease or Do not change the risk.
To keep it privately, answered questions were 
returned in an unmarked envelope in an urn.
The questionnaire was previously tested in a 
convenience sample comprised by 11 university female 
students from UFSCar with the same characteristics as the 
investigated participants in order to confirm the adequacy 
of the instrument, focusing the quality of the obtained 
information.
The collected data were stored in Microsoft Excel 
2010 spreadsheet to calculate absolute, relative and average 
frequencies and were presented according to descriptive 
analysis (frequency and percentage) through tables.
For this article, COC refers to any combination of 
oral contraceptive composition, excluding progestogen oral 
contraceptives and emergency contraception. Participants 
at the time of data collection were using COC or reported 
having used it in the past were named COC users and those 
who never used it were named non-users.
To analyze the questionnaire results, the researchers 
based themselves on the information presented in the 
publication of the World Health Organization (WHO), 
Family Planning - A Global Handbook for Health Service 
Providers4.
RESULTS AND DISCUSSION
From the 86 participants, 74 (86.05%) classified 
themselves as COC users and 12 (13.95%) as non-users. 
Most were young, with a predominance of the age group 
between 18 – 25 years (76.74%). The age ranged from 18 
to 51 years, with an average age of 23.91 years. Single 
marital status (91.86%) and self-declared white (70.93%) 
predominated (Table 1). These results are in accordance 
with the sociodemographic profile of university students 
at Federal Institutions from Sao Paulo State in the year of 
2017, where 84% of them were aged between 18 and 24 
years and 49% declared themselves white12. Specifically, in 
Medical Courses in 2012, the percentage of white students 
enrolled was approximately 75%, similar to the percentage 
observed in our study13.
Table 1. Characteristics of the participants of the study





18 – 21 33 (38.37%)
22 – 25 33 (38.37%)
26 – 29 11 (12.79%)
















   Evangelical Christian Church 12 (13.95%)
Spiritism 11 (12.79%)
Other religions 2 (2.33%)
Health Care System 
Additional 50 (58.14%)
SUS 36 (41.86%)
Federal University of Sao Carlos
Note: N = total number of respondents; n = absolute frequency; % = 
relative frequency; COC = combined oral contraceptive; SUS = Unified 
Health System.
Regarding religious affiliation, 61.7% of university 
students declared to have any religion, predominantly 
Catholic (32.56%), followed by Evangelical Christian 
426
Pinto Pinto LFA, et al. Knowledge of risks and benefits of combined oral contraceptives.
Church (13.95%) and Spiritism Religion (12.79%) (Table 
1). There was a higher prevalence of religion absence 
among COC users (40.54%) than in non-users (25%). 
However, it was not possible to evaluate the religion 
influence on the use of this method, since the sexual history 
was not investigated, and the non-use may be associated 
with the absence of sexual activity at the time of this 
research.
When asked about the health care system used, 
the majority (58.14%) indicated having access to 
supplementary health care (Table 1). Studies indicate 
a decrease in the use of the Brazilian Unified Health 
System (SUS) as family income and education rises. In 
2014, Ristoff13 demonstrated that while 7% of Brazilian 
families had incomes higher than 10 minimum wages, 
44% of medical students’ families were in this salary range. 
Specifically, among medical students at UFSCar, this rate 
was 20.6% in 201615. The major use of supplementary 
health care by participants may be related to their family’s 
socioeconomic profile. 
Regarding the contraceptive history, most COC 
users adhered to the method by medical indication 
(94.59%), only 5.41% used it according to friends and 
family suggestion and none of them discussed the matter 
with their respective partners (Table 2). In 2016, Farias16, 
studying the use of oral and injectable contraceptives in 
Brazil, found that the use of COC in 90.4% of the cases 
was indicated by the doctor, corroborating our findings. 
In contrast, Simionescu’s17 research of European medical 
students showed that 75.41% shared the contraceptive 
choice with their partners, 53.23% with family members 
and only 46.77% with their doctors. 
These data suggest that, in Brazil, medical opinion 
is the one that contributes most to the decision of women in 
choosing the contraceptive method whereas friends, family 
and partners play a secondary role in this contribution. 
Partner participation refers more to supporting women 
in the purchase and use of the method, as well as in the 
eventual use of a male contraceptive method when a 
female method is temporarily discontinued18. Although 
there is a certain degree of change in the participation 
of men in family life, women are still seen in society as 
responsible for controlling its fertility and actions related 
to contraception are concentrated mainly in this sex. In 
addition, the fact that the repercussions of an unscheduled 
pregnancy generally fall on women further reinforces the 
stigma of female responsibility for preventing pregnancy19.
The main reasons cited for choosing COCs for 
contraception were efficacy (29.73%) and accessibility 
(28.38%), followed by ease of use (17.57%) and other 
reasons (17.57%) (Table 2). In fact, the effectiveness of 
COCs is an expressive attraction, because when used 
correctly and consistently, only 0.3 women in 100 become 
pregnant during the first year of use1,4. A research study of 
Portuguese university students showed a tendency to opt 
mostly to pills use due to its high effectiveness and ease of 
use, as observed in our study20. 
Among COC users, 59.46% discontinued its use. 
When asked about the reasons that led them to interrupt 
the method, 70.45% reported concerns about health risks 
and side effects. Among non-users, a similar situation was 
observed with 66.67% of women, indicating that these 
concerns were the main reasons why not using the method 
(Table 2).
Machiyama21 suggests that health injury concerns 
represent the main reasons for not adhere to the method, 
exposing women to unplanned pregnancy, an important 
factor in maternal morbidity and mortality8. On the other 
hand, when women have a positive perception in the 
information about the COC effectiveness in controlling 
fertility, the adherence is significantly higher22. 
This fact made us reflect on whether the participants’ 
decision to abandon the method was a consequence of 
inefficient contraceptive counselling, which was not 
expected, since the majority (94.59%) started the method 
on medical advice.
Table 2. Participants’ contraceptive history
Background 
COC users (N = 74) n (%)
 Indicated by 
Doctor 70 (94.59%)
Friends and/or family 4 (5.41%)
Another health professional 0 (0%)
Partner 0 (0%)
Other 0 (0%)
Reasons for using it
Efficiency 22 (29.73%)
Easy access 21 (28.38%)
Ease of use 13 (17.57%)
Other reasons 13 (17.57%)





Discontinued reasons (N = 44)
Concerns about the risk/side effects 31 (70.45%)
   Other reasons 13 (29.55%)
Non-COC users (N = 12) n (%)
Reasons for not using COC 
Concerns about the risks/side effects 8 (66.67%)
Other reasons 4 (33.33%)
Federal University of Sao Carlos
Note: N = total number of respondents; n = absolute frequency; % = 
relative frequency; COC = combined oral contraceptive.
The data in Table 3 suggests that the knowledge 
about COC health benefits is, in part, satisfactory, since 
more than half of the participants knew about the potential 
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of the method in reducing acne (83.72%), dysmenorrhea 
(83, 72%) and hirsutism (67.44%). On the other hand, 
important non-contraceptive benefits, such as a reduction 
in the occurrence of endometrial (31.40%), ovarian 
(18.60%) and colorectal (8.14%) cancers, as well as ectopic 
pregnancy (EP) (25.58%) and pelvic inflammatory disease 
(PID) (13.95%) were poorly recognized)
Lack of data regarding the protective effects have 
been found in other studies conducted among German23 
and Chinese women24. For example, Vogt23 in a study of 
German women aged 18 to 24 years, found that they were 
unable to associate COC with the reduction of endometrial 
and ovarian cancers. Yang24 found that 68.2% of Chinese 
obstetricians/gynecologists were awareness of PID 
reduction by COC use. We were surprised that this lack 
of knowledge is not restricted to laywomen in general but 
could be extended to those ones who work at the health area.
Regarding health risks, most participants had 
adequate knowledge about the possibility of the occurrence 
of deep venous thrombosis (97.67%) and stroke (88.37%) 
during COC use (Table 3). Similar to our findings, 
Phiplipson23 observed that Romanian university students 
recognized stroke (73%) and thrombosis (70%) as risk 
conditions associated with COC. However, in the study 
conducted by Vogt23 56% of young German women did not 
know whether the use of COCs could increase the risk of 
thrombosis, 20% had denied such an association and 12% 
had recognized the increased risk and that it was a serious 
health consequence. Américo9 found that among Brazilian 
women aged 10 to 49 years most of them had no knowledge 
about COC complications and only 1.9% related to deep 
vein thrombosis with prolonged use of this method. In the 
present study, since the interviewed participants are young 
university students from the health field, the conclusion 
that most of them have knowledge about the risks of VTE 
related to COC use may not agree with the general Brazilian 
society’s pattern due to their higher access to information.
Most participants (58.14%) indicated COC 
beneficial effect in cervical cancer reduction, while 25.58% 
associated it with an increase in the probability of this 
occurrence (Table 3). The comparison of our results with 
other authors revealed a low prevalence of knowledge on 
this topic2,23. In a recent study carried out in the United 
Kingdom26, cancer incidence was evaluated in more than 
40,000 women using and not using COCs over a period 
of 44 years and it was demonstrated that the occurrence 
of cervical cancer does not appear to be influenced by 
long-term use of this method. With statistical significance, 
in cases of current or recent use (less than 5 years) there 
was a slight increase in its incidence. However, this risk 
regresses with the interruption of the method and is equal 
to that presented by non-users after 5 to 15 years.
Regarding breast cancer, 48.84% of the participants 
considered that COC use does not change the risk and 
37.21% reported it does change (Table 3). The close results 
between not changing the risk and increasing it, is in line 
with literature data, which are conflicting and of hard 
analysis, as published by the WHO in Family Planning - A 
Global Handbook for Healthcare Providers4. Conversely, 
the study by Mørch27 suggests an increased risk of breast 
cancer in COC users, being even greater when 10 years 
or more of its use. In the same sense, Iversen26 showed 
increased risk in COC women using it for less than five 
years and that this risk disappears a few years after its 
suspension. However, these same studies demonstrate that 
the absolute risk is very low and that any effect appears 
to be temporary and limited to current or recent use, with 
no influence at later stages of life, when this disease is 
more prevalent26,27. In addition, WHO4 points out that it is 
unclear whether this increased risk with short-term use of 
COC is related to a biological contraceptive effect on the 
development of the disease or the earlier diagnosis of this 
disease among the users.
Estrogens play a fundamental role in the modulation 
and exacerbation of headache, with fluctuations in its 
levels, either downwards, as observed in the period before 
menstruation, or an increase related to the COC beginning 
of use could exacerbate the headache28. Among COC users 
this effect deserves attention, since it may be a reason for 
discontinuing the method4,25. The participants showed 
adequate knowledge on the topic, since 68.60% mentioned 
that the use of COC is associated with an increase in this 
side effect (Table 3).
Another association cited by the majority (65.12%) 
was a decrease in libido. The role of COCs on sexual 
function is not yet well established. In a meta-analysis 
published in the Journal of women’s health (2017)29 on the 
subject, there were studies indicating that there may be an 
increase, neutrality or decrease in libido in users of this 
method depending on the route of administration and the 
type of progestogen present in the formulation. The lack of 
consensus in the peer-reviewed papers reflects the difficulty 
of isolating the effect of contraception on sexual response, 
since factors such as relationship with the partner, psycho-
social problems and even psychiatric illnesses (depression) 
can interfere with libido4.
The estrogens present in COCs increase the hepatic 
synthesis of angiotensinogen, which, in turn, raises 
systemic blood pressure from the rennin-angiotensin-
aldosterone system30. In healthy women, the use of COC 
may cause a slight increase in blood pressure within the 
normal range, which regresses after the interruption of 
its use4. Mastalgia and escape bleeding are also common 
initial side effects of using COC and tend to improve with 
its time of use1,6. The participants demonstrated a fragility 
of knowledge regarding these side effects, since more than 
half of them (54.65%) indicated that COCs do not have 
effects on blood pressure, while the frequency of responses 
indicating increased or decreased mastalgia and escape 
bleeding showed a similar distribution pattern (Table 3).
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In the document Family Planning - A Global 
Handbook for Healthcare Providers4, the WHO mentions 
that in the female population in general there are 
misconceptions about COC effects on fertility, fetal 
formation and development and body weight. In general, 
the university students pointed out that infertility (79.07%) 
and fetal malformation (82.56%) are not related to the use 
of COC, demonstrating an adequate perception. However, 
they considered that they can cause an increase in body 
weight (56.98%) (Table 3), which does not correspond with 
current knowledge on the topic. The use of COC does not 
appear to result in significant changes in weight, either in 
gain or decrease4,6, but since weight variations are natural 
throughout life, women often confuse these changes as 
consequences of using the method4.
Table 3. Frequency of responses in relation to the knowledge about COC of the study participants
Knowledge (n = 86)
Health Benefits Reduces Does not change Increases
Acne 72 (83.72%) 6 (6.98%) 8 (9.3%)
Dysmenorrhea 72 (83.72%) 10 (11.63%) 4 (4.65%)
Hirsutism 58 (67.44%) 20 (23.26%) 8 (9.3%)
Endometrial cancer 27 (31.40%) 41 (47.67%) 18 (20.93%)
Ovarian cancer 16 (18.60%) 52 (60.47%) 18 (20.93%)
Colorectal cancer 7 (8.14%) 70 (81.40%) 9 (10.47%)
Ectopic pregnancy 22 (25.58%) 53 (61.63%) 11 (12.79%)
PID 12 (13.95%) 53 (61.63%) 21 (24.42%)
Health Risks
DVT 0 (0%) 2 (2.33%) 84 (97.67%)
CVA 9 (10.47%) 1 (1.16%) 76 (88.37%)
Cervical cancer 50 (58.14%) 14 (16.28%) 22 (25.58%)
Breast cancer 12 (13.95%) 42 (48.84%) 32 (37.21%)
Side effects
Headache 9 (10.47%) 18 (20.93%) 59 (68.60%)
Decreased libido 9 (10.47%) 21 (24.42%) 56 (65.12%)
Increased blood pressure 2 (2.33%) 47 (54.65%) 37 (43.02%)
Mastalgia 29 (33.72%) 23 (26.74%) 34 (39.54%)
Escape bleeding 34 (39.53%) 16 (18.60%) 36 (41.87%)
Myths
Weight gain 5 (5.81%) 32 (37.21%) 49 (56.98%)
Infertility 2 (2.33%) 68 (79.07%) 16 (18.60%)
Fetal malformation 3 (3.49%) 71 (82.56%) 12 (13.95%)
Federal University of Sao Carlos
Note: n = absolute frequency; % = relative frequency; COC = combined oral contraceptive; PID = pelvic inflammatory 
disease; DVT = deep venous thrombosis; CVA = cerebrovascular accident (CVA).
CONCLUSIONS
The present study demonstrated that the majority of 
participants used COC during the data collection or used it 
in the past, and its use was initiated under medical advice. 
While the effects of COC in increasing the risk of VTE 
and in protecting and decreasing the occurrence of acne, 
dysmenorrhea and hirsutism were recognized, a significant 
portion of the participants associated the use of the method 
with weight gain and were unaware of significant benefits in 
reducing PID, pregnancy ectopic and endometrial, ovarian 
and colorectal cancers. Among the participants who never 
used the method or discontinued it, concerns about health 
risks and side effects were an important reason for this 
decision.
In view of this scenario, the imbalance between 
knowledge about the risks and benefits of COC cannot 
be underestimated, since many misunderstandings can 
be present even among more educated women with 
access to health services, in order to interfere in a more 
conscious choice about the use or not of COCs. Thus, it is 
of paramount importance that health professionals perform 
qualified contraceptive counselling, identifying such factors 
related to the benefits and side effects of COC that may 
interfere with adherence to the method.
429
Rev Med (São Paulo). 2020 Sept-Oct;99(5):423-31.
Annex 1: Instrument of data collection
SECTION 1: SOCIODEMOGRAPHIC CHARACTERISTICS
1) Age:
2) Marital status: (    ) single (    ) married (    ) divorced
 (    ) in stable union (    ) widow
3) Religion: (    ) Catholic (    ) Evangelical Christian Church (    ) Spiritism 
 (    ) none (    ) other: ………
4) Referred color: (    ) white (    ) black (    ) brown 
 (    ) yellow (    ) indigenous
5) Health Care System you currently use: 
(    ) SUS (    ) Supplementary health (health insurance and private)
SECTION 2: CONTRACEPTIVE BACKGROUND
6) Do you use the combined oral hormonal contraceptive (contraceptive pill)?
(    ) never used 
(    ) I already used it, but I abandoned this method 
(    ) I currently use the pill
7) If you have already used the pill and currently do not use it anymore, did the health risks and side effects influence your 
decision to abandon this method?
(    ) Yes  (    ) No
8) If you never used the pill, did the health risks and side effects influence your decision not to use this method?
(    ) Yes (    ) No
9) If you use the pill, what was the main reason that led you to choose this method (Check only 1 answer)
(    ) easy access 
(    ) effectiveness in preventing pregnancy 
(    ) ease of use
(    ) health security 
(    ) affordable price (    ) other reason: …………..
10) If you use the pill, who recommended to you use it? 
(    ) doctor 
(    ) another health professional 
(    ) friends and / or family 
(    ) sexual partner (    ) other: ………..
SECTION 3: KNOWLEDGE
Regarding the risk of the events below, do you believe that the use of the pill can:
11) Acne 
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk 
12) Headache  
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
13) Decreased libido
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
14) Weight gain  
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
15) Hirsutism (increased amount of hair in women in places usual for men such as chin, around nipples, between breasts, buttocks 
and inner thighs) 
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk 
16) Mastalgia (breast pain)
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
17) Spotting (inter-menstrual bleeding from escape) 
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
18) Deep venous thrombosis 
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
19) Stroke (stroke) 
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
20) Increase in blood pressure
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
21) Dysmenorrhea (colic pain during menstruation) 
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
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22) Ectopic pregnancy (pregnancy outside the womb) 
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
23) Pelvic inflammatory disease (Infection in the uterus, tubes, ovaries and / or pelvis) 
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
24) Infertility 
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
25) Fetal malformation 
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
26) Breast cancer  
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
27) Cancer of the cervix  
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
28) Endometrial cancer  
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
29) Ovarian cancer 
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
30) Colorectal cancer 
(    ) Increase the risk (    ) Decrease the risk (    ) Does not change the risk
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